Experienced in Richter Syndrome

Dr. Edward H. Kaplan

Hematology Oncology | Oncology
City Of Hope Medical Group Of Illinois PLLC
9300 Waukegan Rd, 
Morton Grove, IL 
Accepting New Patients
Offers Telehealth
44 Years of Experience
Experienced in Richter Syndrome
City Of Hope Medical Group Of Illinois PLLC
9300 Waukegan Rd, 
Morton Grove, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edward Kaplan is a Hematologist Oncology specialist and an Oncologist in Morton Grove, Illinois. Dr. Kaplan has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Kaplan is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Advocate Lutheran General Hospital
Midwestern Region Med Center, Inc
Northwest Community Hospital 1
Swedish Hospital
Northshore University Healthsystem - Evanston Hospital
Languages Spoken
English
Greek
Hebrew
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL GROUP OF ILLINOIS PLLC
9300 Waukegan Rd, Morton Grove, IL 60053
Other Locations
CITY OF HOPE MEDICAL GROUP OF ILLINOIS PLLC
160 E Illinois St, Chicago, IL 60611
CITY OF HOPE MEDICAL GROUP OF ILLINOIS PLLC
2520 Elisha Ave, Zion, IL 60099

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)
A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Journal: Veterinary medicine and science
Published: November 06, 2018
Similar Doctors
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (14.3 miles away)
866-587-4322
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shuo Ma is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ma has been practicing medicine for over 32 years and is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration.

Distinguished in Richter Syndrome
Dr. Syed N. Haider
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Syed N. Haider
Hematology Oncology | Hematology | Oncology

Froedtert South Inc

9555 76th St, 
Pleasant Prairie, WI 
 (36.1 miles away)
262-577-8300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Syed Haider is a Hematologist Oncology specialist and a Hematologist in Pleasant Prairie, Wisconsin. Dr. Haider is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Paget Disease of the Breast. Dr. Haider is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. Ebenezer A. Kio
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Ebenezer A. Kio
Hematology Oncology | Hematology | Oncology

The University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (20.7 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ebenezer Kio is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Kio is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Non-Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia (CLL). Dr. Kio is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaplan's expertise for a condition
ConditionClose
    View All 31 Advanced Conditions
    View All 106 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile